<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00217529</url>
  </required_header>
  <id_info>
    <org_study_id>PSOC 2001</org_study_id>
    <secondary_id>PSOC-2001</secondary_id>
    <secondary_id>AVENTIS-PSOC-2001</secondary_id>
    <secondary_id>PSOC-IRB-5689</secondary_id>
    <secondary_id>CDR0000441312</secondary_id>
    <nct_id>NCT00217529</nct_id>
  </id_info>
  <brief_title>Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer</brief_title>
  <official_title>A Phase I-II Study of OSI-774 (Tarceva, Erlotinib) With Docetaxel/Carboplatin Followed by Maintenance Therapy With Tarceva as Treatment for Newly Diagnosed Stage III/IV Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Tube Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Drugs used in chemotherapy, such as docetaxel and carboplatin, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving erlotinib together with docetaxel and carboplatin may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when&#xD;
      given together with docetaxel and carboplatin and to see how well they work in treating&#xD;
      patients with newly diagnosed stage III or stage IV ovarian epithelial, primary peritoneal&#xD;
      cavity, or fallopian tube cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) of erlotinib when administered in combination&#xD;
           with docetaxel and carboplatin as front-line therapy in patients with newly diagnosed&#xD;
           stage III or IV ovarian epithelial, primary peritoneal cavity, or fallopian tube cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the toxicity of maintenance therapy with erlotinib when administered after&#xD;
           front-line therapy in these patients.&#xD;
&#xD;
        -  Determine the proportion of patients who are able to receive the full schedule of&#xD;
           treatment courses.&#xD;
&#xD;
        -  Determine the objective response rate in patients with measurable or evaluable disease&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of erlotinib.&#xD;
&#xD;
        -  Front-line therapy: Patients receive docetaxel IV over 1 hour and carboplatin IV over 30&#xD;
           minutes on day 1, pegfilgrastim subcutaneously on day 2, and oral erlotinib once daily&#xD;
           on days 3-16. Treatment repeats every 21 days for up to 6 courses.&#xD;
&#xD;
      Cohorts of 5 patients receive escalating doses of erlotinib until the maximum tolerated dose&#xD;
      (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 5 patients&#xD;
      experience dose-limiting toxicity.&#xD;
&#xD;
        -  Maintenance therapy: Beginning 3-4 weeks after the completion of front-line therapy,&#xD;
           patients with stable or responding disease receive oral erlotinib once daily for up to&#xD;
           12 months.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months for 1 year and then&#xD;
      periodically thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of erlotinib</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of maintenance therapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who receive the full schedule of treatment courses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ovarian epithelial, primary peritoneal cavity, or fallopian&#xD;
             tube cancer&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
          -  The following histologic epithelial cell types are allowed:&#xD;
&#xD;
               -  Serous adenocarcinoma&#xD;
&#xD;
               -  Mucinous adenocarcinoma&#xD;
&#xD;
               -  Clear cell adenocarcinoma&#xD;
&#xD;
               -  Endometrioid adenocarcinoma&#xD;
&#xD;
               -  Mixed epithelial carcinoma&#xD;
&#xD;
               -  Undifferentiated carcinoma&#xD;
&#xD;
               -  Transitional cell carcinoma&#xD;
&#xD;
               -  Malignant Brenner tumor&#xD;
&#xD;
               -  Adenocarcinoma not otherwise specified&#xD;
&#xD;
          -  Must have undergone appropriate surgery for ovarian epithelial, primary peritoneal&#xD;
             cavity, or fallopian tube cancer within the past 6 weeks&#xD;
&#xD;
          -  No borderline ovarian tumor of low malignant potential&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  GOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Alkaline phosphatase (AP) normal AND AST or ALT ≤ 5 times upper limit of normal&#xD;
                  (ULN)&#xD;
&#xD;
               -  AP ≤ 2.5 times ULN AND AST or ALT ≤ 1.5 times ULN&#xD;
&#xD;
               -  AP ≤ 5 times ULN AND AST or ALT normal&#xD;
&#xD;
          -  No hepatic disease that would preclude study participation&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  No renal disease that would preclude study participation&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF ≥ lower limit of normal*&#xD;
&#xD;
          -  No poorly controlled arrhythmia&#xD;
&#xD;
          -  No unstable coronary artery disease&#xD;
&#xD;
          -  No myocardial infarction within the past year NOTE: *LVEF evaluation performed only on&#xD;
             patients requiring it&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No other nonmalignant systemic disease that would preclude study participation&#xD;
&#xD;
          -  No history of severe hypersensitivity reaction to docetaxel or other drugs formulated&#xD;
             with polysorbate 80&#xD;
&#xD;
          -  No medical, social, or psychosocial factor that would preclude study participation&#xD;
&#xD;
          -  No psychiatric or addictive disorder that would preclude giving informed consent&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix or breast&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior immunotherapy for this malignancy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior chemotherapy for this malignancy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No prior hormonal therapy for this malignancy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy for this malignancy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No planned interval cytoreductive surgery&#xD;
&#xD;
               -  Second-look surgery allowed&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 1 year since prior experimental or investigational therapy&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation with warfarin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leona A. Holmberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dan Veljovich, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pacific Gynecology Specialists</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pacific Gynecology Specialists</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington School of Medicine</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>September 20, 2010</last_update_submitted>
  <last_update_submitted_qc>September 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2010</last_update_posted>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>peritoneal cavity cancer</keyword>
  <keyword>ovarian clear cell cystadenocarcinoma</keyword>
  <keyword>ovarian endometrioid adenocarcinoma</keyword>
  <keyword>ovarian undifferentiated adenocarcinoma</keyword>
  <keyword>ovarian mucinous cystadenocarcinoma</keyword>
  <keyword>ovarian serous cystadenocarcinoma</keyword>
  <keyword>Brenner tumor</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>ovarian mixed epithelial carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

